James Harte on Asundexian and Milvexian’s Strong, Dose-dependent Interferences in Coagulation Assays
James Harte, Assistant Lecturer/PhD Candidate on the School of Biochemistry and Cell Biology at University College Cork, proudly reposted from JTH Journal on LinkedIn:
”Delighted to see our work on the laboratory testing of asundexian, milvexian, from the EOLAS Research Group, shared by the Journal of Thrombosis and Haemostasis (JTH).”
JTH Journal shared on LinkedIn:
”Interferences associated with the factor XIa inhibitors asundexian and milvexian in routine and specialized coagulation assays and their removal by activated charcoal-based adsorbents.
This study shows that the emerging FXIa inhibitors asundexian and milvexian produce strong, dose-dependent interferences in coagulation assays — potentially leading to misinterpretation of hemostatic function.
Importantly, activated charcoal–based adsorbents (including DOAC-Stop) effectively removed these interferences, enabling accurate coagulation testing in treated plasma.”
Read the full paper here.
Article: Interferences associated with the factor XIa inhibitors asundexian and milvexian in routine and specialized coagulation assays and their removal by activated charcoal-based adsorbents
Authors: Gavin Buckley, Maeve Crowley, James Harte
Stay updated on all science in the field of coagulation disorders with Hemostasis Today.
-
Aug 18, 2025, 23:54TNF-α–Mediated Platelet Dysfunction: Inflammation, Autophagy Inhibition, and Thrombosis Risk
-
Aug 18, 2025, 23:53Radiotherapy and VTE Risk: Insights from Marc Carrier and Colleagues
-
Aug 18, 2025, 23:52PCI and Bleeding Risk: Shea E. Hogan Reviews Aspirin-Free Approaches
-
Aug 18, 2025, 23:49Ahmed Kotb: HHT Management—Choosing the Right Therapy?
-
Aug 18, 2025, 23:48Pulmonary Embolism Management: Experts Share Valuable Insights on Endovascular Today
-
Aug 20, 2025, 05:48James Harte on Asundexian and Milvexian's Strong, Dose-dependent Interferences in Coagulation Assays
-
Aug 19, 2025, 18:18Hélène Gleitz-Broeders: Targeting Stromal Crosstalk to Reverse Bone Marrow Fibrosis
-
Aug 19, 2025, 17:58David Tregouet on Molecular Determinants of Thrombosis Recurrence Risk Across VTE Subtypes
-
Aug 19, 2025, 17:36Omid Seidizadeh: Effect of Some Polymorphic Variants on the Platelet-Dependent VWF Activity Assays
-
Aug 18, 2025, 23:54Davide Capodanno Shares FITTER Trial: Evolocumab Shows No Added Short-Term Benefit in Acute Coronary Syndrome
-
Aug 18, 2025, 23:56Dr. Arun V. J Invites You to His Lecture on ‘AI and Data Sciences in Transfusion Medicine’ at the AI in Healthcare Conclave. Register now!
-
Aug 18, 2025, 23:50Safe and Efficient Thrombectomy with Artix System: Clinical Insights from Neil Desai and Colleagues
-
Aug 16, 2025, 14:42Mark Crowther Honors Davide Matino for Leading Promising Hemophilia Trial at McMaster University
-
Aug 14, 2025, 10:28Impressive 95% Clot Removal in a VTE Case: Symphony16F and Symphony24F Catheters
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Aug 19, 2025, 17:22Louise Bannon Encourages You to Support World Thrombosis Day!
-
Aug 17, 2025, 07:31Melissa Korn's story: Recognizing Pulmonary Embolism Symptoms Can Save Lives, NBCA
-
Aug 16, 2025, 14:18Christelle Orlando Highlights Breakthroughs in Thrombophilia Testing and AT Assays at ISTH 2025
-
Aug 15, 2025, 23:33Kacper Odziomek Excels in 2 Pharmacology Courses from Harvard Medical School
-
Aug 15, 2025, 03:44Call for Global Action on Bleeding Disorders from Baumann, Christoforou and Klamroth